Summary
The good therapeutic results obtained in the treatment of chronic liver diseases with the protein-free livertotal-extract “Ripason” led us to investigate the action of the extract in rats with experimental liver injury. Sulfobromophtalein clearance, total liver lipids and blood-serum proteins were determined in CCl4 poisoned and in partially hepatectomised rats. It was shown that the extract improved the liver function, that it had a lipotropic action and that the fall in the blood serum albumin resulting from liver injury could be prevented to a considerable degree.
References
B. Jasinski, Schweiz. Med. Wschr.83, 5, 112 (1953).
H. Kalk undE. Wildhirt, Helv. med. Acta19, H. 4/5 (1952).
D. Koch-Weser, E. Farber undH. Popper, Arch. Path.51, 498 (1951).
G. H. Higgins undR. M. Anderson, Arch. Path.12, 186 (1931).
R. Emmrich undH. Petzold, Arch. Exp. Path. Pharmakol.214, 333 (1952).
D. Koch-Weser, E. Farber undH. Popper, Arch. Path.51, 498 (1951).
C. M. Szego undS. Roberts, J. Biol. Chem.178, 827 (1949).
R. S. Long undE. E. Simmons, Arch. intern. Med.88/6, 762 (1951).
F. Scheiffarth undG. Berg, Z. ges. exp. Med.119, 550 (1952).
Author information
Authors and Affiliations
Additional information
« Ripason » der Robapharm Laboratoriums-AG., Basel.
Rights and permissions
About this article
Cite this article
Burri, M. Zur tierexperimentellen Prüfung eines neuen Lebertotalextraktes. Experientia 9, 385–387 (1953). https://doi.org/10.1007/BF02167646
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02167646